


IMPROVEMENT in MASLD & associated diseases e.g. T2DM, CVD, CKD, heart failure and certain cancers



Glucagon receptor agonism potentially reduces lipid content, increases glycogen flux and improves mitochondrial turnover and function

DIRECT HEPATIC EFFECT of GLUCAGON RECEPTOR AGONIST via liver expressed glucagon receptors